Group One Trading’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-100
Closed -$1.14K 9113
2025
Q2
$1.14K Sell
100
-900
-90% -$8.54K ﹤0.01% 7536
2025
Q1
$6.65K Buy
+1,000
New +$9.32K ﹤0.01% 6506
2024
Q4
Sell
-300
Closed -$3.69K 7938
2024
Q3
$3.69K Hold
300
﹤0.01% 5989
2024
Q2
$4.05K Sell
300
-20,200
-99% -$273K ﹤0.01% 6028
2024
Q1
$277K Buy
+20,500
New +$124K ﹤0.01% 3282
2023
Q3
Sell
-1,500
Closed -$15.9K 8269
2023
Q2
$15.9K Buy
+1,500
New +$16K ﹤0.01% 6132
2022
Q3
Sell
-200
Closed -$3K 8227
2022
Q2
$3K Buy
+200
New +$3.04K ﹤0.01% 7329
2021
Q2
Sell
-100
Closed -$4K 8563
2021
Q1
$4K Buy
+100
New +$5.69K ﹤0.01% 7301
2020
Q3
Sell
-200
Closed -$5K 6528
2020
Q2
$5K Buy
+200
New +$4.75K ﹤0.01% 5381

Other funds holding STOK

Group One Trading's STOK Position: Q1 2026 in Review

Group One Trading sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 4,110 shares — an estimated $135K sold.

Group One Trading first reported a position in STOK in Q2 2022 and held it in 7 quarters. The position peaked at $1.25M in Q3 2024. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Group One Trading reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 4,110 Stoke Therapeutics shares in Q1 2026, an estimated $135K.
  • Group One Trading first reported a position in Stoke Therapeutics in Q2 2022 and held it in 7 quarters.
  • Group One Trading's Stoke Therapeutics position peaked at $1.25M in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.